Latest New Zealand News

Autosports Group is set to acquire ten Barry Bourke Motors dealerships in Victoria for $34 million, expanding its luxury automotive footprint and strengthening key manufacturer partnerships.

Coventry Group reports a challenging FY25 with revenue slipping 1.7% and EBITDA plunging 40.9%, but early FY26 results show promising recovery driven by cost cuts and ERP system stabilisation.

EROAD Limited reported a 3.3% revenue increase and strong free cash flow in H1 FY26, driven by ANZ market expansion despite a significant North American impairment. The company is focusing on the promising electronic Road User Charges opportunity in Australasia.

Eagle Mountain Mining Limited has lodged a prospectus for a non-renounceable entitlement offer to raise up to A$1.98 million, supporting exploration and development of its copper-gold projects in Arizona, USA. The offer includes attaching options and follows a recent $1.66 million placement.

DGL Group Limited has outlined a clear path to regain its ASX listing following suspension, targeting reinstatement by February or March 2026 pending audit outcomes.

IPH Limited reported solid FY25 profit growth driven by Canadian acquisitions and a promising FY26 start despite challenges in Australia and New Zealand. CEO Andrew Blattman announced his retirement for late 2026, marking a pivotal leadership transition.

Turners Automotive Group has posted a resilient and record first-half result for FY26, with net profit before tax up 13% despite ongoing economic challenges. The company’s diversified model and strategic capital moves underpin its confident outlook.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

The a2 Milk Company has raised its FY26 revenue guidance, citing stronger-than-expected performance in key product categories and favourable currency movements. The company anticipates solid earnings growth and robust cash flow conversion.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

ParagonCare reported solid FY25 results, progressing well on its complex merger integration and expanding its footprint in Asia through the acquisition of Somnotec Group.

Experience Co Limited reported a strong FY25 with record revenue and earnings growth, driven by its Skydiving and Adventure Experiences segments. The company is advancing organic growth and acquisitions while maintaining disciplined capital management heading into FY26.